Compass Therapeutics Aktie News

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) and progression-free survival (PFS) are expected in late Q1 2026. A new response in a third indication has been observed in the fifth and final dosing cohort of...

CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies. In vivo, CTX-10726 outperformed select competitive antibodies in the class, including ivonescimab, in controlling tumor growth across multiple xenograft and syngeneic models.

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November. Details are as follows: Guggenheim 2nd An...

Compass Therapeutics, Inc. (NASDAQ:CMPX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT Company Participants Thomas Schuetz - CEO & Vice Chairman Barry Shin - Chief Financial Officer Conference Call Participants Kelly McCarthy Presentation Kelly McCarthy Good afternoon, everyone. This is Kelly McCarthy from the Morgan Stanley Healthcare team, and it's gre...

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September.

Compass Therapeutics' pipeline shows promise, especially with tovecimig's positive phase 2 results in biliary tract cancers and upcoming basket study plans. CTX-8371's early signals in NSCLC and TNBC support dose expansion, with detailed phase 1 data expected in Q4 2025. Preclinical candidate CTX-10726 demonstrates potential superiority to competitors, with an IND submission targeted for Q4 2025.

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pr...

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants t...